Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
OJEMDA: selected primary-label renal guidance and limits
Product / population
OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.
Renal method
Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
OJEMDA: source applicability and renal evidence limits
The primary label has an explicit renal-use recommendation; the retrieved mirror passage is PK-only. Absence of that section in the returned mirror text is not proof of disagreement.
What to reconcile: Use age-appropriate Schwartz/MDRD interpretation and the labeled oncology regimen.
DailyMed / product prescribing information · OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.
Renal method: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
eGFR <30 not studied; no dialysis regimen established.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 8.7
No dose adjustment is recommended for mild-to-moderate impairment with eGFR >=30 mL/min/1.73 m2 using Schwartz or MDRD. Severe impairment below 30 has not been studied. No dialysis regimen is supplied. Use the labeled pediatric oncology indication, BSA-based regimen and appropriate oral presentation; the renal statement does not provide a complete treatment protocol.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
